2019 ASCO Annual Meeting!
Session: EGFR and ROS1: Targeting Resistance
Type: Clinical Science Symposium
Time: Friday May 31, 1:00 PM to 2:30 PM
Location: Hall D1
JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).
Metastatic Non-Small Cell Lung Cancer
Lung Cancer—Non-Small Cell Metastatic
2019 ASCO Annual Meeting
J Clin Oncol 37, 2019 (suppl; abstr 9009)
Author(s): Eric B. Haura, Byoung Chul Cho, Jong Seok Lee, Ji-Youn Han, Ki Hyeong Lee, Rachel E. Sanborn, Ramaswamy Govindan, Eun Kyung Cho, Sang-We Kim, Karen L. Reckamp, Joshua K. Sabari, Meena Thayu, Kyounghwa Bae, Roland Elmar Knoblauch, Joshua Curtin, Nahor Haddish-Berhane, Laurie Jill Sherman, Matthew V. Lorenzi, Keunchil Park, Joshua Bauml; Department of Thoracic Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea; Seoul National University Bundang Hospital, Seoul, South Korea; National Cancer Center, Gyeonggi-Do, South Korea; Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, South Korea; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR; Washington University School of Medicine, St. Louis, MO; Gachon University Gil Medical Center, Incheon, South Korea; Asan Medical Center, Seoul, South Korea; City of Hope Comprehensive Cancer Center, Duarte, CA; NYU School of Medicine, New York, NY; Janssen Research & Development, LLC, Spring House, PA; Janssen Research and Development, Spring House, PA; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background: JNJ-372 binds EGFR and cMet to block ligand binding, promote receptor degradation, and trigger antibody-dependent cellular cytotoxicity in models of EGFR-mutated (EGFRm) NSCLC. Here we describe the ongoing phase 1 safety, pharmacokinetics (PK), and activity of JNJ-372 in patients (pts) with NSCLC, including 3rd generation tyrosine kinase inhibitor (3GTKI)-relapsed EGFRm NSCLC and EGFR Exon20ins disease. Methods: Pts received JNJ-372 (140–1400 mg) IV weekly for the first 28-day cycle and biweekly thereafter. 1050–1400 mg doses are being explored in dose expansion. Blood samples were collected for PK analyses. Efficacy by investigator per RECIST v1.1 in pts with EGFRm NSCLC treated at ≥700 mg is presented. Tumors were characterized by next-generation sequencing of circulating tumor (ct)DNA and/or tumor tissue. Results: As of 17 Jan 2019, 116 enrolled pts with NSCLC were treated. Median age was 63 years, 38% were male, 77% were Asian, and 97% had EGFR mutations. Mean duration of treatment was 3.8 months, longest exposure was 20 cycles. The PK data set included pts from Korea (77%) and the US (23%). At the 1050 mg dose, 72% of pts achieved average concentrations above the EC90 based on preclinical models. Adverse events (AEs; ≥20%) were rash (59%), infusion related reaction (58%), paronychia (28%), and constipation (22%). Additional EGFR/cMet-related AEs include stomatitis (17%), pruritis (15%), peripheral edema (11%), and diarrhea (7%). Grade ≥3 AEs were reported in 34% (8% treatment-related) with dyspnea (6%) and pneumonia (3%) most frequently observed. Among response-evaluable pts, 25/88 (28%) achieved best timepoint response of partial response (PR). 10/47 pts with prior 3GTKI therapy had best timepoint response of PR (6 confirmed), including 4 with C797S, 1 with cMet amplification, and 5 without identifiable EGFR/cMet-dependent resistance. 6/20 pts with Exon20ins had best timepoint response of PR (3 confirmed). Conclusions: JNJ-372 has a manageable safety profile consistent with EGFR and cMet inhibition. Preliminary responses were achieved in 3GTKI-relapsed disease, including C797S and cMet amplification, and Exon20ins disease; enrollment in dose expansion is ongoing. Clinical trial information: NCT02609776